Our Pipeline

BIOSIMILAR DESCRIPTION REFERENCE PRODUCT PRIMARY CONDITIONS

ABP 501
(biosimilar adalimumab)

Anti-Tumour Necrosis Factor-Alpha (Anti-TNF) Monoclonal Antibody
  • Moderate-to-Severe Rheumatoid Arthritis
  • Moderate-to-Severe Chronic Plaque Psoriasis
  • Adult Moderate-to-Severe Crohn’s Disease
  • Moderate-to-Severe Ulcerative Colitis
  • Ankylosing Spondylitis
  • Psoriatic Arthritis
  • Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis

ABP 980
(biosimilar trastuzumab)

Anti-HER2 Monoclonal Antibody
  • HER 2+ Breast Cancer
  • HER 2+ Gastric Cancer

ABP 215
(biosimilar bevacizumab)

Anti-Vascular Endothelial Growth Factor A (Anti-VEGF) Monoclonal Antibody
  • Colorectal Cancer
  • Non-Squamous Non-Small Cell Lung Cancer
  • Glioblastoma
  • Renal Cell Carcinoma
  • Breast Cancer
  • Ovarian Cancer

ABP 798
(biosimilar rituximab)

Anti-CD20 Monoclonal Antibody
  • Non-Hodgkin’s Lymphoma
  • Chronic Lymphocytic Leukemia
  • Rheumatoid Arthritis

ABP 710
(biosimilar infliximab)

Anti-Tumour Necrosis Factor-Alpha (Anti-TNF) Monoclonal Antibody
  • Rheumatoid Arthritis
  • Plaque Psoriasis
  • Crohn’s Disease
  • Ulcerative Colitis
  • Psoriatic Arthritis
  • Ankylosing Spondylitis

ABP 494
(biosimilar cetuximab)

Anti-Epidermal Growth Factor Receptor (Anti-EGFr) Monoclonal Antibody
  • Colorectal Cancer
  • Head and Neck Cancer

 

Notes:

  • Approved product indications will differ by regulatory agency.
  • Amgen has an additional 3 biosimilar programs in product development which are undisclosed at this time.
Inflammation
Oncology